Experimental Therapeutics

Deborah B. Marin and Kenneth L. Davis
Department of Psychiatry
Mount Sinai Medical Center
New York, New York 10029.


1. Altstiel L, Sperber K. Cytokines in Alzheimer's disease. Prog Neuropsychopharmacol Biol Psychiatry 1991;15:481–495.

2. Bauer J, Strauss S, Schreiter-Gasser U, et al. Interleukin-6 and alpha-2-macroglobulin indicate an acute phase response in Alzheimer's disease cortices. FEBS Lett 1991;285:111–114.

3. Behl C, Davis J, Cole GM, et al. Vitamin E protects nerve cells from amyloid B protein toxicity. Biochem Biophys Res Commun 1992;186:944–950.

4. Blessed G, Tomlinson BE, Roth M. The association between quantitative measures of dementia and of senile change in the cerebral grey matter of elderly subjects. Br J Psychiatry 1968;114:797–811.

5. Caporaso GL, Gancy SE, Buxbaum JD, et al. Chloroquine inhibits intracellular degradation but not secretion of Alzheimer B/A4 amyloid precursor protein. Proc Natl Acad Sci USA 1992;89:2252–2256.

6. Chang TMS, Barre P. Effect of desferrioxamine on removal of aluminum and iron by coated charcoal haemoperfusion and haemodialysis. Lancet 1983;1051–1053.

7. Chatellier G, Lacomblez L on behalf of Groupe Francais d'Etude de la Tetrahydroaminoacridine. Tacrine (tetrahydroaminoacridine; THA) and lecithin in senile dementia of the Alzheimer's type: a multi-center trial. Br Med J 1990;495–499.

8. Cheng B, Mattson MP. Glucose deprivation elicits neurofibrillary tangle-like antigenic changes in hippocampal neurons: prevention by NGF and bFGF. Exp Neurol 1992;117:114–123.

9. Clayton RM, Sedowofia SKA, Rankin JM, Manning A. A long term effect of aluminum in the fetal mouse brain. Life Sci 1992;51:1921–1928.

10. Cornfeldt M, Wirtz-Burgger, Szewczak M, Blitzer R, Haroutunian V, Effland RC, Klein JT, Smith C. Abstr Soc Neurosci 1990;16:612.

11. Crutcher KA, Scott SA, Liang S, et al. Detection of NGF-like activity in human brain tissue: increased levels in Alzheimer's disease. J Neurosci 1993;13:2540–2550.

12. Dal-Bianco P, Maly J, Wober C, et al. Galanthamine treatment in Alzheimer's disease. J Neural Transm [Suppl] 1991;59–63.

13. Davidson M, Bierer LM, Kaminsky R, et al. Combined administration of physostigmine and clonidine to patients with dementia of the Alzheimer type: a pilot safety study. Alzheimer's Dis Assoc Disord 1989;4:1–4.

14. Davis KL, Hollander E, Davidson M, et al. Induction of depression with oxotremorine in Alzheimer's disease patients. Am J Psychiatry 1987;144:4.

15. Davis KL, Thal LJ, Gamzu E, et al. Tacrine in patients with Alzheimer's disease: a double blind placebo controlled multicenter study. N Engl J Med 1992;327:1374–1379.

16. Eagger S, Morant N, Levy R, Sahakian B. Tacrine in Alzheimer's disease time course of changes in cognitive function and practice effects. Br J Psychiatry 1992;160:36–40.

17. Elrod K, Buccafusco JJ. Correlation of the amnestic effects of nicotinic antagonists with inhibition of regional brain acetylcholine synthesis in rats. J Pharmacol Exp Ther 1991;403–409.

18. Estus S, Golde T, Kunishita T, et al. Potentially amyloidogenic, carboxyl-terminal derivatives of the amyloid protein precursor. Science 1992;255:726–730.

19. Farlow M, Gracon SI, Hershey LA, Lewis KW, Sadowsky CH, Dolan-Ureno J. A controlled trial of tacrine in Alzheimer's disease. JAMA 1992;2523–2529.

20. Fielding S, Cornfeldt ML, Szewczak MR, et al. HP-029, a new drug for the treatment of Alzheimer's disease: its pharmacological profile. Presented at fourth world conference on clinical pharmacology and therapeutics, Berlin (West), July 28–30, 1989.

21. Fisher A, Brandeis R, Karton I, et al. (±)-cis-2-Methyl-spiro(1,3-oxathiolane-5,3)quinuclidine, an M1 selective cholinergic agonist, attenuates cognitive dysfunctions in an animal model of Alzheimer's disease. J Pharmacol Exp Ther 1991;392–403.

22. Folstein MF, Folstein SE, McHugh PR. "Mini-Mental-State". A practical method for rating the cognitive state of patients for the clinician. J Psychiatry Res 1975;12:189–198.

23. Gauthier S, Bouchard R, Lamontagne A, et al. Tetrahydroaminoacridine–lecithin combination treatment in patients with intermediate-stage Alzheimer's disease. N Engl J Med 1990;322:1272–1276.

24. Haga S, Akai K, Ishii T. Demonstration of microglial cells in and around senile (neuritic) plaques in the Alzheimer brain: an immunohistochemical study using a novel monoclonal antibody. Acta Neuropathol 1989;77:569–575.

25. Haratounian V, Kanof PD, Tsuboyama G, et al. Restoration of cholinomimetic activity by clonidine in cholinergic plus adrenergic lesioned rats. Brain Res 1990;507:261–266.

26. Hollander E, Davidson M, Mohs RC, et al. RS 86 in the treatment of Alzheimer's disease: cognitive and biological effects. Biol Psychiatry 1987;22:1067–1078.

27. Hood WF, Sun ET, Compton RP, et al. 1-Aminocyclo-butane 1-carboxylate (ACBC): a specific antagonist of the N-methyl-D-asoartate receptor coupled glycine receptor. Eur J Pharmacol 1989;161:281–282.

28. Jenike MA, Albert MS, Baer L. Oral physostigmine as treatment for Alzheimer's disease: a long term outpatient trial. Alzheimer's Dis Assoc Dis 1990;4(4):226–231.

29. Kruck TPA. Aluminum in Alzheimer's disease. Is there a link? Nature 1993;363(6425):119.

30. Lawlor BA, Davis KL. Does modulation of glutamatergic function represent a viable therapeutic strategy in Alzheimer's disease? Biol Psychiatry 1992;31:337–350.

31. Leber P. Guidelines for the clinical evaluation of antidementia drugs, first draft. Rockville, MD: US Food and Drug Administration, 1990.

32. Mangoni A, Grassi MP, Frattola L, et al. Effects of a MAO-B inhibitor in the treatment of Alzheimer's disease. Eur Neurol 1991;31(2):100–107.

33. Mohs RC. Neuropsychologic assessment of patients with Alzheimer's disease. In: Bloom FE, Kupfer DJ, eds. Psychopharmacology The Fourth Generation of Progress. New York: Raven Press, 1994:1377–1388.

34. Mohs RC, Davis BM, Johns CA, et al. Oral physostigmine treatment of patients with Alzheimer's disease. Am J Psychiatry 1985; 142:28–33.

35. Monard D. Role of protease inhibition in cellular migration and neuritic growth. Biochem Pharmacol 1987;36:1389–92.

36. McGeer PL, McGeer EG. Complement proteins and complement inhibitors in Alzheimer's disease. Res Immunol 1992;143:621–624.

37. McGeer PL, McGeer EG, Rogers J, et al. Does anti-inflammatory treatment protect against Alzheimer's disease? In: Khachaturian ZS, Blass JP, eds. Alzheimer's disease: new treatment strategies. New York: Marcel Dekker, 1992;165–171.

38. McLachlan Crapper DR, Dalton AJ, Kruck TPA, Bell MY, Smith WL, Kalow W, Andrews DF. Intramuscular desferrioxamine in patients with Alzheimer's disease. Lancet 1991;337:1304–1308.

39. Murphy MF, Hardiman ST, Nash RJ, et al. Evaluation of HP 029 (velnacrine maleate) in Alzheimer's disease. Ann NY Acad Sci 1991;253–262.

40. Newhouse PA, Sunderland T, Tariot PN, et al. Intravenous nicotine in Alzheimer's disease: a pilot study. Psychopharmacology 1988;95:171–175.

41. Nicholson VJ, Tam SW, Myers MJ, et al. DuP996 (3,3-bis(4-pyrindinylmethyl)-1-phenylindolin-2-one) enhances the stimulus-induced release of acetylcholine from rat brain in vitro and in vivo. Drug Rev Res 1990;19:285–300.

42. Nordberg A, Alafuzoff I, Winblad B. Nicotinic and muscarinic subtypes in the human brain: changes with aging and dementia. J Neurosci Res 1992;103–111.

43. Oka A, Belliveau MF, Rosenberg PA, et al. Vulnerability of oligodendroglia to glutamate. Pharmacology, mechanisms, and prevention. J Neurosci 1993;13:1441–153.

44. Olson L, Nordberg A, von Holst H, et al. Nerve growth factor affects C-nicotine binding, blood flow, EEG, and verbal episodic memory in an Alzheimer patient. J Neural Transm 1992;4:79–95.

45. Olton DS, Wenk GL. Dementia: animal models of the cognitive impairments produced by degeneration of the basal forebrain cholinergic system. In: Meltzer HY, ed. Psychopharmacology: the third generation of progress. New York: Raven Press, 1987;941–953.

46. The Parkinson Study Group. Effect of deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 1989; 321:1364–1371.

47. Perry EK, Tomlinson BE, Blessed G, et al. Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. Br Med J 1978;2:1457–1459.

48. Pomara N, Mendels J, Lewitt PA, et al. Multicenter trial of milacemide in the treatment of Alzheimer's disease. Biol Psychiatry [Suppl] 1991;29:718.

49. Raffaele KC, Berardi A, Morris P, et al. Effects of acute infusion of the muscarinic cholinergic agonist arecoline on verbal and visuo-spatial function in dementia of the Alzheimer's type. Prog Neuropsychopharmacol Biol Psychiatry 1991;15:643–648.

50. Read SL, Frazee J, Shapira J, et al. Intracerebroventricular bethanechol for Alzheimer's disease. Variable dose-related responses. Arch Neurol 1990;47:1025–1030.

51. Riekkinen P Jr, Sirvio J, Aaltonen M, et al. Effects of concurrent manipulations of nicotinic and muscarinic receptors on spatial and passive avoidance learning. Pharmacol Biochem Behav 1990;405–410.

52. Robakis NK, Anderson JP, Lawrence MR, et al. Expression of the Alzheimer amyloid precursor in brain tissue and effects of NGF and EGF on its metabolism. Clin Neuropharmacol 1991;14 (Suppl):15–23.

53. Rogers J, Kirby LC, Hempelman SR, et al. Clinical trial of indomethacin in Alzheimer's disease. Neurology 1993;43:1609–1611.

54. Rogers J, Schultz J, Brachova L, et al. Complement activation and B-amyloid-mediated neurotoxicity in Alzheimer's disease. Res Immunol 1992;143:624–630.

55. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry 1984;141(11):1356–1364.

56. Saletu B, Darragh A, Salmon P, et al. EEG brain mapping in evaluating the time course of the central action of DuP 996: a new acetylcholine release drug. Br J Pharmacol 1989;28:1–16.

57. Sapolsky RM, Krey LM, McEwen BS. Prolonged glucocorticoid exposure reduces hippocampal neuron number: implications for aging. J Neurosci 1985;5:1222–1227.

58. Sara SJ, Debaugesw B. Idazoxam, an alpha 2 agonist, facilitates memory retrieval in the rat. Behav Neurol Biol 1989;51:401–411.

59. Schneider LS, Olin JT, Pawluczyk S. A double-blind crossover pilot study of L-deprenyl (selegeline) combined with cholinesterase inhibitors in Alzheimer's disease. Am J Psychiatry 1993;150:21–23.

60. Sheardon MJ, Nielsoen EO, Hansen AJ, et al. 2,3-Dihydroxy-6-nitro-7-sulfamoyl-benzo(F)quinoxaline: a neuroprotectant for cerebral ischemia. Science 1990;247:571–574.

61. Simpson MDC, Royston MC, Deakin JFW, et al. Regional changes in [H]D-aspartate and [H] TCP binding sites in Alzheimer's disease brains. Brain Res 1988;462:850–852.

62. Strittmatter WJ, Saunders AM, Schmechel D, et al. Apolipoprotein E: high-avidity binding to B-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer's disease. Proc Natl Acad Sci USA 1993;90:1977–1981.

63. Sunderland T, Molchan S, Lawlor B, et al. A strategy of "combination chemotherapy" in Alzheimer's disease: rationale and preliminary results with physostigmine plus deprenyl. Int Psychogeriatr 1992;4(Suppl 2):291–309.

64. Suzuki T, Nairn AC, Gandy SE, Greengard P. Neuroscience 1992;48:755–761.

65. Thomsen T, Bickel U, Fischer JP, et al. Galanthamine hydrobromide in a long-term treatment of Alzheimer's disease. Dementia 1990;1:46–51.

66. Tollefson GD. Short-term effects of the calcium channel blocker nimodipine (Bay-e-9736) in the management of primary degenerative dementia. Biol Psychiatry 1990;27:1133–1142.

67. Vantini G. The pharmacological potential of neurotrophins: a perspective. Psychoneuroendocrinology 1992;17:401–410.

68. Watson GB, Bolanowski MA, Baganoff MP, et al. Glycine antagonist action of 1-aminocyclobutane-1-carboxylate (ACBC) in Xenopus oocytes injected with rat brain mRNA. Eur J Pharmacol 1989;167:291–294.

69. Whitehouse PJ. Neuronal loss and neurotransmitter receptor alterations in Alzheimer's disease. In: Fisher JA, Hanin I, Lachman C, eds. Alzheimer's and Parkinson's diseases: strategies for research and development. New York: Plenum Press, 1986;85–94.

70. Willson RL. Free radical protection: why vitamin E, not vitamin C, B-carotene or glutathione? In: Porter R, Whelan J, eds. Biology of vitamin E. Ciba Foundation Symposium 101. London: Pitman, 1983;19–44.

71. Yasuda RP, Ciesla W, Flores LR, et al. Development of antisera selective for m4 and m5 muscarinic cholinergic receptors: distribution of m4 and m5 receptors in rat brain. Mol Pharmacol 43:149–157.

Back to Chapter

published 2000